Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Receivables (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Receivables for 6 consecutive years, with $74.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 97.64% to $74.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $74.4 million, a 97.64% increase, with the full-year FY2025 number at $74.4 million, up 97.64% from a year prior.
  • Receivables was $74.4 million for Q4 2025 at GeneDx Holdings, up from $60.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $74.4 million in Q4 2025 to a low of $498000.0 in Q3 2023.
  • A 5-year average of $36.2 million and a median of $36.7 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: crashed 98.92% in 2023, then soared 7574.7% in 2024.
  • GeneDx Holdings' Receivables stood at $26.6 million in 2021, then surged by 66.15% to $44.1 million in 2022, then fell by 26.65% to $32.4 million in 2023, then grew by 16.24% to $37.6 million in 2024, then surged by 97.64% to $74.4 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Receivables are $74.4 million (Q4 2025), $60.9 million (Q3 2025), and $48.0 million (Q2 2025).